MediVas’ platform technology is based on a next generation set of polymers exclusively licensed from Cornell University.  Generated from research both at Cornell and at MediVas, we currently have an IP portfolio containing over 60 issued or pending US patents.

This family of biodegradable polymers represents a novel approach to drug delivery, capable of generating products across a wide rage of therapeutic areas. These polymers have set a new standard for next generation drug delivery as they are fully biodegradable, biocompatible and bioabsorbable, are non-inflammatory, safe and efficacious, and degrade by surface erosion allowing greater control over the rate and duration of release of their therapeutic payload.

In addition, our polymer based drug delivery system sets us apart from other drug delivery companies because our technology has: 

·          Broad Applicability—MediVas polymer technology can be used with a diverse group of drug candidates, from proteins, peptides and nucleic acids to small molecule drugs.

·          Versatility of formulation—MediVas has created a variety of injectable, oral and intranasal formulations using our polymer-based nanoparticles.

·          Stabilization—MediVas has demonstrated stability with different widely varying compounds, including proteins and nucleic acids, without the loss of their biological activity. 

MediVas is currently focusing its in-house development efforts on three high value areas which leverage our technology’s unique capabilities and serve to highlight its significant advantages.

Please contact us to learn more about the many exciting opportunities in this area.